Key Industry Expert Speakers
9th Market Access, Pricing & Reimbursement Global Congress 2023 Europe
Trends and Strategies to Achieve Optimum Patient Access to Healthcare
4th - 5th May 2023 - Hilton London Kensington , London, UK
- Claudia Neuber, Head, Global Pricing Oncology, Global Market Access & Pricing, AstraZeneca
- Daniel Jackson, Global Head - Market Access Policy, UCB
- Maria Danchenko, Global Market Access Academy Lead, Sanofi
- Silvy Mardiguian, Market Access Director, UK & Ireland, BeiGene
- Marco Rauland, Vice President Global Market Access & Pricing - Strategic Planning, Merck Group
- Ana Plata, Global Pricing Head - BioPharmaceuticals, AstraZeneca
- Elvira Müller, Vice President, Certara Evidence & Access
- Santoke Naal, Director Market Access, IGES U.K. Pharma Ltd
- Rafael Souza, Ph.D Head of Access Solutions & Pricing, New Markets, BeiGene Switzerland GmbH
- Esther Nzenza, Founder and CEO, Decisive Consulting Ltd
- Vasiliki Patsioura, Global Pricing Implementation Lead, Astrazeneca
- Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation Poland
- Dr Alexander Natz, Secretary-General, EUCOPE
- Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
- Maarten Van Baelen, Executive Director, Plasma Protein Therapeutics Association
- Marta Parmar, Head of International Regulatory Affairs, Alexion
- Ryotaro Ishikawa, Global Market Access Director, Novartis
- Jörg Mahlich, Market Access & Government Affairs Lead, Miltenyi Biomedicine
- Olga Katzelnik, Market Access Lead Europe/International, Regeneron
- Nazanin Mehin, Head of Global Diabetes Solutions, Sanofi
- Sara Lopes, Sr. Director, Global Market Access & Pricing Governance, Shionogi
- Andrew Stainthorpe, Head of Market Access, Oxford AHSN
- Marisca Marian, Oncology Market Access Strategy Leader, Bayer
- Jenniffer Cain Birkmose, VP, Global Head of Patient Access and Community Engagement, Sobi - Swedish Orphan Biovitrum AB*
- Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
- Josie Godfrey, Co-Founder and CEO, Realise Advocacy
- David Bower, Principal, Head of Market Access Excellence, Clarion
- Libby Hamson, Senior Manager Market Access (mRNA Vaccines, Antivirals & Internal Medicines), Pfizer

AstraZeneca
Head, Global Pricing Oncology, Global Market Access & Pricing
CLAUDIA NEUBER has been Head of Global Pricing Implementation at AstraZeneca PLC since January 2016 and moved to the newly role of Head of Oncology in fall of 2021. Prior to this role she worked as the Director of Pricing and Contracting at AstraZeneca Canada, in addition she served as vice-chair of the industry pricing committee and served as an industry representative in numerous government consultations. She has over 30 years of industry experience. During this time she has worked in a variety of roles in the areas of Sales, Marketing, Strategic Planning/Finance, Knowledge Management, and Pricing/Access functions. She holds a Bachelor of Science from the University of Toronto and an MBA from the Schulich School of Business. She currently lives in the UK with her husband and two children.

Elvira Müller
Vice President
Elvira Müller is a Vice President at Certara Evidence & Access, responsible for HTA and Evidence Development as well as managing the EvA market access and analytics consulting team based in Germany. She oversees the strategic, scientific, and operational performance with focus on reimbursement strategy and submissions, health technology assessments (HTA) as well as evidence synthesis. Elvira is a specialist in Early engagements with HTA bodies for early dialogues/scientific advice and has substantial expertise in joint European activities through EUnetHTA collaboration (early dialogues, joint assessments, core HTA). For German market needs, she and her team focus on strategy consulting, dossier development and analytics tailored to AMNOG requirements. Elvira looks back on 20 years of experience in global market access following her graduation in natural sciences (MSc, PhD) and public health (MPH).

Maria Danchenko
Global Market Access Academy Lead
Over 15 years with Sanofi, currently leading the Global Market Access Academy. Focusing on developing the strategic capability building and collaborative problem solving for market access colleagues and market access knowledge building of our functional partners. A seasoned market access professional with almost 15 years of experience in the market access arena.
Most recently served as Market Access Lead for AMEE and International regions, responsible for the development and execution of regional market access strategies for Sanofi mature portfolio as well as new launches.
Worked previously in the Global Pricing Team, being responsible for the global pricing strategy of several brands over product lifecycle including peri-LOE, specializing in the IRP impact assessment. Started her career in Market Access Department of the Russian affiliate as Eurasia Pricing Manager. Before her market access experience, Maria worked in several roles and companies within the medical and marketing functions.
Has a degree in Foreign languages from Yaroslavl State Pedagogical University (Yaroslavl, Russia) and a degree in PR & Advertising from Moscow (Lomonosov) State University as well as a European Market Access University Diploma (EMAUD) received from Lyon 1 University (France).

Marco Rauland
Vice President Global Market Access & Pricing - Strategic Planning
Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck, Marco was Vice President Europe of GfKs Market Access practice. Before that Marco was the global head of the pricing, access and reimbursement practice of Genactis and Senior director of the pricing and reimbursement business unit at TNS Healthcare (now Kantar Group). Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing strategies. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.

Vasiliki Patsioura
Global Pricing Implementation Lead
Vasiliki Patsioura- Global Pricing Implementation Lead at Astrazeneca (MSc Health Economics, Policy and Management, LSE)
With more than 10 years of professional experience in pharmaceutical consulting and industry access roles; a health economist by training served as part of the technical team for guidelines development at the National Guidelines Centre (part of NICE); Her interests are around pharmaceutical pricing both strategical and operational and how these can enable access to innovative therapies for patients

LAURA A CLARK-KELLY
Sr. Director
Laura Clark-Kelly has worked with the pharmaceutical industry, health plans, and pharmacy benefit management organizations (PBMs) to enhance their communication, connection, and confidence so that they can have a significant impact on physicians and patients. Her guiding principle has been that people should be able to get the medicines they need at prices they can afford. This passion has led her leadership vision to new heights. Laura has over twenty years of broad base business experience, a knack for making meaningful connections, an insatiable appetite for learning, along with a dedication to assisting others in maximizing their potential. Laura has a deep interest in people, leadership, and making a positive difference in the world. She finds particular motivation in empowering others to achieve personal and professional breakthroughs. She discovered that volunteering was one way she could give back. When she is not ensuring profitable market access for pharmaceutical products, Laura can be found preparing delectable meals, reading beach novels (even in the winter), and spending time with her family, which includes her labradoodle, Henry.

Maarten Van Baelen
Executive Director
Maarten is the Executive Director of the Plasma Protein Therapeutics Association (PPTA). The PPTA is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 1.100 human plasma collection centers in North America and Europe, as well as, the manufacturers of lifesaving plasma-derived medicines. PPTA’s mission is, as a trusted partner to health systems, to drive broad and reliable access to plasma protein therapies, with a focus on the well-being of patients and plasma donors. Prior to joining PPTA in 2019, Maarten worked as Market Access Director and Medical Affairs Manager at Medicines for Europe, the trade association representing the European generic, biosimilar and valued added pharmaceutical industries. In addition, during that time, Maarten was advisor to the Board of the European Medicines Verification Organization (EMVO). After graduating as a pharmacist from KU Leuven, Maarten spent several years working in medical affairs roles in the pharmaceutical and medical devices industry, while also being a practicing pharmacist. Maarten also obtained an MBA from the Solvay Brussels School Economics & Management and the École des Ponts Business School in Paris

Thilo Schaufler
Head of Market Access Nephrology
Dr. Thilo Schaufler, Head of Market Access Nephrology, Vifor Pharma
Thilo Schaufler is a seasoned professional with 15 years’ experience in market access and health policy roles, providing strategic leadership to global and local cross-functional teams to support business growth. He has co-led successful product launches, indication expansions as well as the loss of exclusivity of major assets.
Since 2018, he is responsible for Market Access for Vifor’s global nephrology portfolio. Before that, he held roles of increasing responsibility at Roche, AbbVie, Amgen, and Pfizer. Thilo holds a doctorate in health economics from the University of Mannheim and a dual degree in political sciences and economics.